Sept 27 (Reuters) - The U.S. Food and Drug
Administration has approved Sanofi and Regeneron's
blockbuster drug Dupixent for patients with a chronic
lung disease commonly known as "smoker's lung", the companies
said on Friday.
(Reporting by Sriparna Roy in Bengaluru; Editing by Sriraj
Kalluvila)